Actuate Therapeutics Submits IPO Registration

Actuate Therapeutics, Inc., a biopharmaceutical company based in CHICAGO and FORT WORTH, Texas, has announced its intentions to go public. The company submitted a registration statement to the Securities and Exchange Commission (SEC) for an initial public offering (IPO) of its common stock on May 28, 2024. However, details such as the number of shares to be offered and the price range have yet to be disclosed. The success and timing of the IPO remain uncertain, as they depend on market conditions and other factors.

Actuate plans to list its common stock on the Nasdaq Capital Market under the ticker symbol “ACTU.” Titan Partners Group, a division of American Capital Partners, will serve as the sole book-running manager for the offering, while Newbridge Securities Corporation will act as the co-manager. The offering will be conducted solely through a prospectus, which can be obtained from Titan Partners once it becomes available.

The registration statement filed with the SEC is still pending effectiveness. Consequently, no sales or offers to buy the securities can occur until the registration statement is effective. The press release clarifies that it does not constitute an offer to sell or a solicitation to buy, and no sales will be made in jurisdictions where such actions would be illegal without proper registration or qualification under local securities laws.

Actuate Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for high-impact cancers. Its leading drug candidate, elraglusib, is a novel GSK-3 inhibitor targeting cancer-related molecular pathways that promote tumor growth and resistance to traditional treatments such as chemotherapy. Elraglusib aims to enhance anti-tumor immunity by inhibiting NF-kB, thereby regulating multiple immune checkpoints and immune cell functions. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!